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Palliative Thoracic Radiotherapy in Locally Advanced
Non-small Cell Lung Cancer: Can Quality-Of-Life
Assessments Help in Selection of Patients for Short- or
Long-Course Radiotherapy?
Stein Sundstrøm,*† Roy M. Bremnes,‡§ Paal Brunsvig, Ulf Aasebø,‡¶ and Stein Kaasa,*†
for The Norwegian Lung Cancer Study Group
Purpose: Patient-assessed health-related quality-of-life (HRQOL)
scores, together with demographic and clinical factors in stage III
non-small cell lung cancer (NSCLC) patients, are important prog-
nostic factors for survival and may be helpful in determining
thoracic radiotherapy (TRT) strategy.
Methods: In a previously published randomized trial, 301 patients
were treated with different palliative radiotherapy schedules, com-
paring short-term hypofractionated TRT (arm A: 17 Gy/2 fractions
[n  105]) with more protracted TRT (arm B: 42 Gy/15 fractions
[n  104]); arm C: 50 Gy/25 fractions [n 92]). Baseline HRQOL,
demographic, and clinical data were available for all patients. All
possible prognostic factors from univariate analysis were entered
into the Cox multivariate regression model to identify variables of
independent prognostic relevance.
Results: Overall survival was similar, whereas long-term survival
was restricted to higher-dose radiotherapy with 3-year survival
rates of 1, 8, and 6% (p  0.40) and 5-year survival rates of 0,
4, and 3% (p  0.12) in arms A, B, and C, respectively. In
univariate analysis, Karnofsky performance status, use of anal-
gesics, and weight loss were highly significant non-HRQOL
factors (p  0.001), and physical function, appetite loss, cough,
and pain were the most powerful HRQOL factors (p  0.001). In
multivariate analysis, appetite loss appeared as the most powerful
independent prognostic indicator. In the group of patients treated
with protracted fractionation (n  196), the 2-, 3-, and 5-year
survival rates in patients with no appetite loss (n  95) were 22%
(21/95), 12% (11/95), and 8% (8/95) compared with 3% (3/101),
1% (1/101), and 1% (1/101) in patients with appetite loss present
at baseline (n  101).
Conclusion: In addition to performance status and weight loss,
patient-reported appetite loss should be assessed in stage III NSCLC
patients before administrating TRT; such assessment is a valuable
tool for selecting patients to normofractionated or lower-dose hypo-
fractionated palliative TRT.
KeyWords: Palliative radiotherapy, Stage III non-small, Prognostic
factors.
(J Thorac Oncol. 2006;1: 816–824)
During the last decade, health-related quality-of-life(HRQOL) issues have been established as important
endpoints in clinical trials.1 Quality-of-life assessment
should be patient-assessed using validated questionnaires
including general health and disease- and symptom-spe-
cific questions. Traditionally, HRQOL has supplied impor-
tant information in addition to clinical outcome measures
such as tumor response and survival. For studies on non-
curative therapies in cancer patients, HRQOL has emerged
as one of the most import endpoints for treatment effect.2
HRQOL data have been shown to supply significant prog-
nostic information in a variety of cancers.3,4 In lung
cancer, baseline HRQOL data are strong prognosticators in
both curative and palliative settings.5–8 In advanced
NSCLC patients, it has been shown that HRQOL assess-
ments during the first 6 weeks of chemotherapy are good
predictors for both response and survival.9
Although there is an increasing use of chemotherapy
in locally advanced non-small cell lung cancer (NSCLC),
palliative thoracic radiotherapy (TRT) remains important
for palliation of intrathoracic symptoms in patients pro-
gressing during chemotherapy or when chemotherapy is
not indicated or feasible. Hypofractionated (10–17 Gy)
TRT and higher-dose TRT (40–60 Gy) are equally effec-
tive in their palliative effects on disease-related symp-
toms.10–12 However, a Cochrane analysis gave evidence
for a modestly increased survival (6% at 1 year and 3% at
2 years) in favor of higher-dose radiotherapy in patients
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with good performance status (PS) and localized disease.13 In a
study by the Norwegian Lung Cancer Study Group,12 a trend to
better 3-year survival in stage III patients with good PS (Karnof-
sky PS 80) was observed.
The aim of this study was to examine the predictive
value of baseline HRQOL data in patients with stage III
disease scheduled for palliative TRT, in comparison with
demographic, clinical, and treatment variables. The research
question is whether HRQOL data can be of help in the
selection of hypofractionated versus higher-dose TRT in
patients with locally advanced NSCLC.
MATERIALS AND METHODS
Patients and Staging
A total of 301 patients with stage III disease who com-
pleted baseline HRQOL questionnaires and were treated with
three different palliative TRT regimens were included in this
analysis. A complete description of the total study population
and inclusion criteria has been published previously.12 The
general inclusion criteria were confirmed histology or cytology
consistent with NSCLC, age 18, stage III disease, Karnofsky
PS40%, completed baseline HRQOL questionnaire, expected
survival2 months, and centrally located tumor causing airway
symptoms or without symptoms but threatening central airways.
Among patients with stage IIIA disease, traditionally with more
favorable prognosis, only inoperable patients with poor prog-
nostic factors such as tumor diameter 7 cm, Karnofsky PS
70%, or weight loss 10% during the last 6 months were
eligible. Previous chemotherapy was allowed, but earlier TRT
led to ineligibility.
At inclusion, all patients were staged based on physical
and radiological examinations (chest x-ray and computed
tomography of the chest including liver and adrenal glands).
Cerebral computed tomography or cerebral magnetic reso-
nance imaging and bone scans were performed only if symp-
toms. The patients were categorized according to the 1986
clinical stage classification.14 Baseline laboratory determinants
(cell counts, erythrocyte sedimentation rate, alkaline phospha-
tase, lactate dehydrogenase, gamma glutamyl transpeptidase,
and neuron specific enolase) were registered, together with
Karnofsky PS, use of analgesics and/or steroids, and weight loss
during the last 6 months.
TRT
TRT was given as two opposing anterior–posterior fields
individually encompassing the regional mediastinal lymph
nodes and the primary tumor with a 1.5- to 2-cm margin. The
following fractionation schemes were used: armA, two fractions
of 8.5 Gy on days 1 and 8 for a total dose of 17 Gy; arm B, 15
fractions of 2.8 Gy for a total dose of 42 Gy; and arm C, 25
fractions of 2 Gy for a total dose of 50 Gy. In arm B, a filter was
inserted in the posterior field to reduce radiation dose to the
spinal cord to 2.6 Gy per fraction, thereby not exceeding an
equivalent dose value of 1180 ret. Using the cumulative radia-
tion effect formula,15 the radiobiological effects were equivalent
in arms B and C. The maximal portal length, exposing the spinal
cord, was set to 12 cm.
HRQOL
The European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire and the lung
cancer–specific module (QLQ-LC13) were used to measure
HRQOL.16,17 The core questionnaire incorporates five func-
tional scales (physical, role, emotional, cognitive, social),
three symptom scales (fatigue, nausea/vomiting, pain), a
global health and overall quality-of-life scale, and five single
items (dyspnea, appetite loss, sleep disturbance, constipation
and diarrhea, and financial impact of the disease and its
treatment). The QLQ-LC13 module contains items for mea-
suring dyspnea, cough, hemoptysis, mucositis, dysphagia,
peripheral neuropathy, alopecia, pain, and analgesic consump-
tion/effect. All scales and single items were linearly transformed
to a 0 to 100 scale, with a higher score on functional scales
indicating a high degree of function and a higher score on the
symptom scales indicating more symptoms.
Prognostic Factors
Clinical variables possibly predicting survival in NSCLC
were categorized at baseline. Laboratory blood determinants
were dichotomized according to normal and elevated values.
Karnofsky PS status and weight loss were each divided into
three different categories (Karnofsky PS 90–100, Karnofsky PS
70–80, and Karnofsky PS 60 for Karnofsky PS and none,
10%, and 10% for weight loss). Histology was catego-
rized in squamous or nonsquamous differentiation, and use of
analgesics and steroids were divided in used or not used.
The scores in the HRQOL scales or single symptoms
are continuous variables and are not easy to interpretate in the
clinic. Dichotomized HRQOL variables are more easily com-
prehensible and were chosen as the preferred presenting
method in this report. The HRQOL baseline scores were dichot-
omized according to  median score or  median score in the
functional scales and  median score or  median score in the
symptom scales.
Statistical Analysis
The Cancer Research Trial Office at the University
Hospital in Trondheim performed the randomization based on
a block-randomization method. Baseline HRQOL data were
calculated using group scores for the mean value of each
variable.18 Univariate survival analyses related to baseline
HRQOL, demographic, and clinical factors were performed
using the method of Kaplan-Meier.19 Survival was deter-
mined on an intention-to-treat basis from the first day of TRT,
and the log-rank test was applied for comparison of survival.
All variables with p values of less than 0.10 in the univariate
analysis were entered into the multivariate analysis using the
proportional hazards model of Cox.20 Probability for forward
stepwise entry and removal was set at 0.05 and 0.10, respec-
tively. The significance level was set at 0.05 using a two-
sided test.
RESULTS
Patient Population, Treatment, and Survival
Based on a previously published randomized trial with
421 included individuals, 301 patients with localized stage III
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disease who completed baseline HRQOL questionnaires con-
stituted this study. Patient characteristics are presented in
Table 1. Females accounted for 23%, and the median age was
68 years (range, 41–88). The majority of patients were
categorized as Karnofsky PS 70–80. Only 7% had PS 60 or
below. Close to one third had major (10%) weight loss.
There were no significant differences between the treatment
arms regarding stage, histology, and lab tests. About half of
the patients had squamous cell histology. Compliance of
baseline HRQOL questionnaires was 99%, with equal distri-
bution of baseline HRQOL scores in all treatment arms (data
not shown).
Sixteen patients terminated TRT prematurely (one in
arm A, eight in arm B, and eight in arm C [p  0.03]). Only
six patients were treated with chemotherapy during follow-
up, but none of these survived for more than 18 months.
Other palliative therapies were irradiation to symptomatic
metastatic sites and best supportive care.
All patients were followed until death or for at least 5
years. There was no significant difference in survival (p 0.53)
between the treatment arms, as shown in Figure 1. Median
survival was 9.2, 7.5, and 7.5 months in arms A, B, and C,
respectively. There was a trend towards more long-term
survivors in arms B and C, even though this difference did
TABLE 1. Baseline Characteristics of All Patients (n  301) According to Assigned Treatment
All Arm A Arm B Arm C
n  301 n  105 n  104 n  92 p value
Gender (%)
Male 77 81 80 68 0.08
Female 23 19 20 32
Age (yr)
Median 68 68 69 68.5 0.21
Range 41–88 44–88 44–86 41–84
Karnofsky scale (%)
60 7 10 5 5
70–80 58 54 60 59 0.53
90–100 36 35 36 36
Weight loss (%)
None 40 42 33 44
10 % 32 28 42 25 0.09
10 % 29 30 25 31
Stage (%)
IIIA 18 20 18 15 0.68
IIIB 82 80 82 85
Histology (%)
Squamous cell carcinoma 52 52 53 51 0.97
Nonsquamous 48 48 47 49
LDH (U/l) (%)
Normal 70 75 68 66 0.36
Elevated (450) 30 25 32 34
ALP (U/l) (%)
Normal 79 83 77 76 0.40
Elevated (270) 21 17 23 24
NSE (g/l) (%)
Normal 78 79 79 75 0.75
Elevated (13) 22 21 21 25
ESR (mm/h) (%)
50 48 44 49 52 0.49
50 52 56 51 48
GT (U/l) (%)
Normal 78 83 79 71 0.16
Elevated (women 50, men 80) 22 17 21 29
Hemoglobin (g/dl) (%)
Normal 50 45 47 60 0.08
Anemia (women 11, 5; men 13, 5) 50 55 53 40
LDH, lactate dehydrogenase; ALP, alkaline phosphatase; NSE, neuron specific enolase; ESR, erythrocyte sedimentation rate; GT, gamma glutamyl transpeptidase.
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not reach statistical significance. However, long-term survi-
vors were almost exclusively treated within the prolonged
fractionated treatment arms. The 3- and 5-year survival rates
were 1 and 0% in arm A; 8 and 6% in arm B; and 4 and 3%
in arm C.
Univariate Analysis
Univariate analysis results for baseline demographic,
clinical, and laboratory values (non-HRQOL) are presented
in Table 2. No differences within stage IIIA and stage IIIB
were revealed. Analysis of continuous and dichotomized
HRQOL variables gave similar results. Because of the easier
interpretation of dichotomized variables, the results from
dichotomized scores are presented in Table 3. Of 17 evalu-
ated non-HRQOL factors, nine were statistically significant.
The most prominent factors were Karnofsky PS (p  0.0001,
Figure 2), weight loss (p  0.001), use of analgesics (p 
0.001), use of steroids (p  0.01), white blood cell count
(p  0.01), and platelet count (p  0.01). Of 16 different
baseline HRQOL scores, all but one (cognitive function)
were of possible prognostic relevance (p  0.05). Appetite
loss (p  0.0001, Figure 3) and cough (p  0.0001) were
highly significant, and physical function, nausea and vomit-
ing, pain, and hemoptysis also were strong indicators of
survival (p  0.001).
Multivariate Analysis
All statistically significant variables from the univariate
analysis were included in a Cox multivariate regression
analysis (11 non-HRQOL, 15 HRQOL variables [p  0.10]).
Because data were missing for 41 cases, 260 patients were
included in this analysis. Appetite loss (p  0.001), use of
steroids (p  0.019), and role function (p  0.022) were
found to independently predict survival, whereas physical
function had borderline significance (Table 4). Karnofsky PS,
weight loss, and the other highly significant baseline HRQOL
factors from the univariate analysis (nausea and vomiting,
pain, cough, hemoptysis) did not reach statistical significance
in this model.
Appetite loss was dichotomized in  median score
versusmedian score and emerged in this model as the most
significant independent predictor for survival. Median score
in the appetite scale was 0 (not at all). In that respect, any
reported loss of appetite will indicate limited survival.
Among those 196 patients treated with prolonged fraction-
ation (arm B, arm C), the combined 2-, 3-, and 5-year survival
rates were 12% (24/196), 6% (12/196), and 5% (9/196). In
comparison, the 2-, 3-, and 5-year survival rates in patients
with no appetite loss at baseline treated with protracted
fractionation (n  95) were 22% (21/95), 12% (11/95), and
8% (8/95), respectively.
DISCUSSION
The present study was carried out to identify possible
prognostic indicators by assessing HRQOL items in addi-
tion to demographic and clinical variables at baseline.
Baseline HRQOL scores may be difficult to interpret and
use in routine daily practice as a basis for treatment
selection. Because the interpretation of dichotomized
HRQOL variables is more comprehensible than interpre-
tation of continuous variables, this method of presenting
the data was chosen in this report.
With regard to treatment effect on disease-related symp-
toms in advanced NSCLC, hypofractionated palliative TRT is
equivalent to normofractionated higher-dose TRT.10–13 Even
though the treatment is palliative, there is a limited potential
for long-term survival in localized disease.12,13 In the present
study, which was restricted to stage IIIA and IIIB patients
considered not suitable for curative radical TRT, some long-
term survivors were observed in the higher-dose treatment
arms. These few patients seem to be cured for their lung
cancer, consistent with the Cochrane analysis,13 indicating a
modest increase of long-term survival in localized disease
patients with good PS who are given high-dose fractionated
palliative TRT.
In the study by Macbeth et al.21 evaluating 39 Gy/13
fractions versus 17 Gy/2 fractions, the 1- and 2-year survival
rates were 36 and 12% versus 31 and 9%, respectively, in
favor of the prolonged fractionation scheme. This difference,
persistent also at 3- and 4-year follow-up time, was observed
in patients with good PS. However, there was no prognostic
analysis in this study.
In a three-arm study comparing 50 Gy/25 fractions
versus twice 20 Gy/5 fractions versus observation alone,
Reinfuss et al.22 observed 2-year survival rates of 12, 6, and
0%. In this study, survival beyond 2 years was not reported,
and no prognostic factor analyses were performed. In a recent
Dutch study comparing 30 Gy/10 fractions versus 16 Gy/two
fractions, a 3-year survival rate of 5.6 versus 1.6% in favor of
the higher-dose TRT was observed.23 On the other hand,
several randomized studies comparing hypofractionated TRT
with higher-dose schedules10,24–28 did not reveal long-term
survival differences.
FIGURE 1. Overall survival according to treatment arm (p 
0.53). Arm A: 8.5 Gy  2 (n  105); arm B: 2.8 Gy  15
(n  104), arm C: 2.0 Gy  25 (n  92).
Journal of Thoracic Oncology • Volume 1, Number 8, October 2006 Prognostic Significance of HRQOL in Advanced NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 819
TABLE 2. Univariate Analysis. Baseline Demographic and Clinical Parameters as Predictors for Disease-Specific Survival after
Treatment with Radiotherapy (n  301).
No. of patients Median survival (months) p value (log-rank test)
Gender
Male 231 8.5 0.97
Female 70 9.2
Age (yr)
65 112 6.8 0.60
65 189 9.5
Type of radiotherapy
8.5 Gy  2 105 9.2
2.8 Gy  15 104 7.5 0.47
2.0 Gy  25 92 7.5
Karnofsky performance status
90–100 107 11.5
70–80 173 7.5 0.0001
60 21 3.2
Weight loss (%)
None 117 10.3
10 94 7.3 0.0007
10 85 6.1
Extent of disease
Stage IIIA 54 9.6 0.48
Stage IIIB 247 7.9
Histology
Squamous cell carcinoma 157 9.6 0.22
Nonsquamous 144 7.2
ESR (mm/h)
50 137 9.4 0.012
50 146 7.3
Hemoglobin (g/dl)
Normal 151 9.5 0.063
Anemia (women 11, 5; men 13, 5) 150 7.5
WBC count (109/l)
10 175 10.2 0.002
10 126 6.4
Platelet count (109/l)
400 209 9.5 0.004
400 92 6.2
LDH (U/l)
Normal 205 9.3 0.056
Elevated (450) 89 7.2
Alkaline phosphatase (U/l)
Normal 233 9.3 0.042
Elevated (270) 62 6.8
-glutamyl transferase (U/l)
Normal 228 9.4 0.031
Elevated (women 50, men 80) 65 6.0
NSE (g/l)
Normal 191 9.3 0.16
Elevated (13) 55 7.5
Use of steroids
No 234 9.5 0.0063
Yes 67 5.0
Use of analgesics
No 226 9.6 0.0004
Yes 75 6.1
ESR, erythrocyte sedimentation rate; WBC, white blood cell; LDH, lactate dehydrogenase; NSE, neuron specific enolase.
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It is well known that the survival expectation for the
majority of patients with advanced NSCLC is limited. Thus,
palliative TRT should use a minimum of patient-time and
radiotherapy resources for the community. In that respect,
short-term hypofractionated palliative TRT is a good alterna-
tive. The challenge is to identify the minority of patients who
TABLE 3. Univariate Analysis. Baseline Health-Related Quality-of-Life Scores (Dichotomized According to Median Values) as
Predictors for Disease-Specific Survival after Treatment with Radiotherapy (n  301)
No. of patients Median survival (months) p value (log-rank test)
Physical function (median score  60)
 median score 76 5.8 0.0001
 median score 225 9.6
Role function (median score  50)
 median score 62 6.8 0.042
 median score 237 9.3
Emotional function (median score  75)
 median score 115 7.3 0.032
 median score 186 9.2
Cognitive function (median score  100)
 median score 148 7.2 0.12
 median score 153 9.6
Social function (median score  83.33)
 median score 145 6.4 0.001
 median score 152 10.3
Global quality of life (median score  58.33)
 median score 144 6.8 0.001
 median score 155 10.7
Fatigue (median score  44.44)
 median score 112 6.8 0.01
 median score 188 9.7
Nausea and vomiting (median score  0)
 median score 62 5.1 0.0008
 median score 238 9.6
Pain (EORTC C-30) (median score  16.67)
 median score 123 6.4 0.0001
 median score 178 10.5
Dyspnea (EORTC C-30) (median score  66.67)
 median score 52 4.0 0.022
 median score 249 9.6
Appetite loss (median score  0)
 median score 146 6.8 0.0001
 median score 153 10.8
Sleep disturbance (median score  33.33)
 median score 71 5.5 0.004
 median score 227 9.5
Constipation (median score  0)
 median score 134 7.3 0.017
 median score 166 9.6
Diarrhea (median score  0)
 median score 55 4.9 0.0089
 median score 245 9.5
Cough (LC-13) (median score  33.33)
 median score 82 5.1 0.0001
 median score 218 9.8
Hemoptysis (median score  0)
 median score 87 6.6 0.0004
 median score 213 9.8
EORTC C-30, European Organisation for Research and Treatment of Cancer core questionaire; LC-13, lung cancer–specific module.
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might benefit from a higher-dose normofractionated palliative
TRT schedule.
In our multivariate analyses, appetite loss emerged as
the most significant independent indicator for survival in this
cohort of patients, whereas Karnofsky PS and weight loss did
not reach significance. This finding was surprising because
the prognostic significance of PS on survival is well docu-
mented in localized stage III disease.29–31 On the other hand,
HRQOL items have been evaluated to a much lesser extent as
prognostic factors in NSCLC. Kaasa et al.5 and Ganz et al.6
demonstrated the prognostic significance of patient-rated
quality-of-life items. Subsequent studies using the European
Organisation for Research and Treatment of Cancer core
questionnaire and the QLQ-LC13 module (as in our study)
confirmed baseline HRQOL data as valuable prognostica-
tors.32,33 The study by Montazeri et al.32 in 129 localized and
metastatic lung cancer patients identified physical function,
role function, global quality of life, pain, and fatigue as
significant prognosticators in univariate analyses. In the sub-
sequent multivariate analysis, only global quality of life was
identified as a predictor for survival, along with disease stage
and age. Langendijk et al.8 investigated the prognostic role of
baseline HRQOL scores in 198 patients treated with radical
radiotherapy. In univariate analyses, appetite loss, fatigue,
and global quality of life were found to have prognostic
significance, whereas global quality of life remained the only
significant prognostic HRQOL predictor in the multivariate
analysis, along with classical clinical prognosticators such as
N-stage and weight loss. In 206 advanced NSCLC patients
receiving palliative chemotherapy, Herndon et al.33 reported
pain, appetite loss, fatigue, lung cancer symptoms, global
quality of life, and physical function to be of prognostic
significance in the univariate analysis. Here, pain was the
only HRQOL item with independent prognostic value in the
multivariate analysis.
To our knowledge, no previous trial restricted to stage
III NSCLC disease treated with palliative TRT has investi-
gated the influence of baseline HRQOL scores as prognostic
factors. In our study, appetite loss was identified as the most
powerful independent factor. Because any patient-reported
loss of appetite is easily accessible, this variable seems
valuable as a prognostic indicator used in routine clinical
practice.
Retrospectively, when this palliative radiotherapy
trial was performed, stage IIIB patients were most often
considered beyond curative potential with radiotherapy
alone. Since the trial was completed, our policy has
changed, with more patients treated with high doses of 60
to 66 Gy with or without concomitant chemotherapy. The
most valuable result from this secondary analysis of the
stage III population is that it seems possible to cure some
patients with even a palliative dose of TRT, although not
with a hypofractionated schedule.
In conclusion, patients with no appetite loss and
otherwise favorable prognostic factors should be treated
with a higher-dose normofractionated or curative intended
schedule (if they are candidates for TRT) and not short-
term hypofractionated TRT. Appetite loss at baseline
seems to be one of the most important prognostic indica-
tors in localized stage III NSCLC and should be assessed
before TRT planning. The value of this prognostic factor in
lung cancer patients given high-dose radiotherapy should
be further explored in prospective randomized clinical
trials.
FIGURE 2. Overall survival of all patients (n  301) ac-
cording to Karnosky PS status with median survival of 3.2,
7.5, and 11.5 months (p  0.0001) and 2- and 5-year
survival of 0 and 0%, 8 and 2%, and 21 and 7% in PS
60 (n  21), PS 70–80 (n  173) and PS 90–100
(n  107), respectively.
FIGURE 3. Overall survival of all patients (n  301) accord-
ing to appetite loss with median survival of 6.8 and 10.8
months (p  0.0001) and 2-, 3-, and 5-year survival of 4
and 19%, 1 and 8%, and 1 and 5% in patients with appe-
tite loss present (n  146) versus those with no appetite loss
(n  153).
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